Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01420068 · ClinicalTrials.gov registry record

52-104 Week Off-therapy Second Extension to Study CSPP100A2365

A clinical trial of Hypertension, sponsored by Noden Pharma.

Completed
Registry status
106
Enrollment target
20
Study locations

NCT01420068 is a study of Hypertension that has completed, run by Noden Pharma. The registered enrollment target is 106 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01420068, a study of Hypertension, has completed, sponsored by Noden Pharma.

COMPLETED
Registry status
106 participants
Enrollment target
20
Study locations

Study Summary

52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1

Conditions Studied

Hypertension

Interventions

  • DRUG SPP100

Study Locations (20)

Other

  • Novartis Investigative Site - Guatemala City
  • Novartis Investigative Site - Budapest
  • Novartis Investigative Site - Nyíregyháza
  • Novartis Investigative Site - Szeged
  • Novartis Investigative Site - Veszprém
  • Novartis Investigative Site - Warsaw
  • Novartis Investigative Site - San Juan
  • Novartis Investigative Site - Bratislava
  • Novartis Investigative Site - Martin

Mississippi

  • Novartis Investigative Site - Hattiesburg
  • Novartis Investigative Site - Jackson

Oregon

  • Novartis Investigative Site - Portland
  • Novartis Investigative Site - Portland

Alabama

  • Novartis Investigative Site - Birmingham

Arkansas

  • Novartis Investigative Site - Little Rock

Georgia

  • Novartis Investigative Site - Dalton

Idaho

  • Novartis Investigative Site - Lewiston

New York

  • Novartis Investigative Site - New York

Trial Details

FieldValue
Enrollment Target 106 participants
Start Date 2011-08-19
Est. Completion 2017-08-03

Sponsor

Noden Pharma

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01420068

The ClinicalTrials.gov registry entry for NCT01420068 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The listed sponsor is Noden Pharma, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which SPP100 is the first listed.

NCT01420068 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Other, Mississippi, Oregon.

Frequently Asked Questions

What is clinical trial NCT01420068 about?

NCT01420068 is a clinical study titled "52-104 Week Off-therapy Second Extension to Study CSPP100A2365". 52-104 week off-therapy second extension to study CSPP100A2365 to assess growth and development in pediatric hypertensive patients previously treated with aliskiren in studies SPP100A2365 and SPP100A2365E1

What is the current status of trial NCT01420068?

This trial is currently completed. The enrollment target is 106 participants. The study started on 2011-08-19. Estimated completion is 2017-08-03.

What conditions does trial NCT01420068 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT01420068?

The interventions under investigation include: SPP100 (DRUG).

Who is sponsoring clinical trial NCT01420068?

This trial is sponsored by Noden Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01420068 being conducted?

This trial has 20 study locations across Alabama, Arkansas, Georgia, Idaho, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.